Related Experiment Videos
Bronchogenic carcinoma in patients under age 40
J G Antkowiak1, A M Regal, H Takita
1Department of Thoracic Surgery and Oncology, Roswell Park Memorial Institute, Buffalo, NY 14263.
The Annals of Thoracic Surgery
|March 1, 1989
Summary
Young adults with lung cancer (bronchogenic carcinoma) present with advanced disease and aggressive tumors. Survival is poor, with median survival of 7.5 months, indicating a need for earlier detection and treatment strategies.
Area of Science:
- Oncology
- Pulmonology
- Cancer Research
Background:
- Bronchogenic carcinoma, or lung cancer, is uncommon in young adults (19-39 years).
- This demographic often presents with advanced disease and unique tumor characteristics.
- Understanding lung cancer in young patients is crucial for developing targeted therapies.
Purpose of the Study:
- To analyze the clinical characteristics and outcomes of young patients diagnosed with bronchogenic carcinoma.
- To compare the aggressiveness and survival rates of lung cancer in young adults versus older populations.
- To identify factors influencing prognosis in this specific patient group.
Main Methods:
- Retrospective analysis of 89 patients aged 19-39 diagnosed with bronchogenic carcinoma between 1973-1983.
- Data collection included patient demographics, smoking history, tumor histology, disease stage at diagnosis, and survival data.
- Statistical analysis to determine median survival and prognostic factors.
Main Results:
- Adenocarcinoma and large cell undifferentiated carcinoma were the most common histologies (49% and 30%, respectively).
- The majority of patients presented with advanced disease (Stage IIIA, IIIB, or IV: 95%).
- Median survival was 7.5 months overall, and 17.5 months for surgically resected tumors. Only 3 patients survived.
Conclusions:
- Young adults with lung cancer exhibit aggressive disease with short survival durations.
- Advanced stage at diagnosis is a significant characteristic of lung cancer in this age group.
- Lung cancer in younger patients may represent a distinct, more aggressive clinical entity requiring further investigation.